Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients

Liane M McGlynn, Tove Kirkegaard, Joanne Edwards, Sian Tovey, David Cameron, Chris Twelves, John M S Bartlett, Timothy G Cooke

Research output: Contribution to journalArticlepeer-review

Abstract

The expression and activation of the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathway plays an important role in the development and progression of cancer, and may influence response to treatments such as tamoxifen and chemotherapy. In this study we investigated whether the expression and activation of the key components of this pathway influenced clinical outcome, to test the hypothesis that activation of the MAPK pathway drives resistance to tamoxifen and chemotherapy in women with breast cancer.
Original languageEnglish
Pages (from-to)1487-95
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients'. Together they form a unique fingerprint.

Cite this